INFLAMMATION RESEARCH-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=1233497, encodeId=8a94123349e82, content=偏重的研究方向：炎症;慢性痛 经验分享：审稿速度很慢，Editor appointed之后日期状态换过一次，状态没变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c04b1788757, createdName=ms4708251035500551, createdTime=Tue Jul 19 21:59:37 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149644, encodeId=af1721496441f, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：自身炎症性疾病 经验分享：去年9月投稿，今年7月接收，非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b21e5489896, createdName=魏骐骄, createdTime=Mon Jul 24 21:16:50 CST 2023, time=2023-07-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1247519, encodeId=5346124e5191e, content=四月份投的，现在还是reviewers invited..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Tue Sep 06 18:41:59 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098271, encodeId=d25020982e136, content=我9月初接受，大概什么时可以Proof 谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Thu Nov 03 16:27:30 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096843, encodeId=ad7120968432f, content=我的9月初接受，大家accept之后多久收到proof? 谢谢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Fri Oct 28 16:53:33 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094312, encodeId=b3fd20943120e, content=大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:51:10 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094313, encodeId=21f3209431371, content=请问大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:56:13 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236071, encodeId=f06412360e13e, content=Quality check in progress一般持续多久。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue Aug 02 00:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243361, encodeId=63001243361f7, content=审稿速度:1.0 经验分享：我想投难度大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16de5579986, createdName=ms4000001485474384, createdTime=Mon Sep 05 20:54:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199900, encodeId=d822119990079, content=偏重的研究方向：炎症 经验分享：杂志还是不错的，但是最近在pubpeer上也有几篇被质疑的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=12509f90m28暂无昵称, createdTime=Sun Mar 06 14:22:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]

2022-07-19 ms4708251035500551

偏重的研究方向：炎症;慢性痛
经验分享：审稿速度很慢，Editor appointed之后日期状态换过一次，状态没变

58 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1233497, encodeId=8a94123349e82, content=偏重的研究方向：炎症;慢性痛 经验分享：审稿速度很慢，Editor appointed之后日期状态换过一次，状态没变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c04b1788757, createdName=ms4708251035500551, createdTime=Tue Jul 19 21:59:37 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149644, encodeId=af1721496441f, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：自身炎症性疾病 经验分享：去年9月投稿，今年7月接收，非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b21e5489896, createdName=魏骐骄, createdTime=Mon Jul 24 21:16:50 CST 2023, time=2023-07-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1247519, encodeId=5346124e5191e, content=四月份投的，现在还是reviewers invited..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Tue Sep 06 18:41:59 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098271, encodeId=d25020982e136, content=我9月初接受，大概什么时可以Proof 谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Thu Nov 03 16:27:30 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096843, encodeId=ad7120968432f, content=我的9月初接受，大家accept之后多久收到proof? 谢谢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Fri Oct 28 16:53:33 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094312, encodeId=b3fd20943120e, content=大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:51:10 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094313, encodeId=21f3209431371, content=请问大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:56:13 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236071, encodeId=f06412360e13e, content=Quality check in progress一般持续多久。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue Aug 02 00:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243361, encodeId=63001243361f7, content=审稿速度:1.0 经验分享：我想投难度大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16de5579986, createdName=ms4000001485474384, createdTime=Mon Sep 05 20:54:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199900, encodeId=d822119990079, content=偏重的研究方向：炎症 经验分享：杂志还是不错的，但是最近在pubpeer上也有几篇被质疑的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=12509f90m28暂无昵称, createdTime=Sun Mar 06 14:22:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]

2023-07-24 魏骐骄来自山东省

审稿速度:12.0 | 投稿命中率:50.0
偏重的研究方向：自身炎症性疾病
经验分享：去年9月投稿，今年7月接收，非常慢

35 0

[GetPortalCommentsPageByObjectIdResponse(id=1233497, encodeId=8a94123349e82, content=偏重的研究方向：炎症;慢性痛 经验分享：审稿速度很慢，Editor appointed之后日期状态换过一次，状态没变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c04b1788757, createdName=ms4708251035500551, createdTime=Tue Jul 19 21:59:37 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149644, encodeId=af1721496441f, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：自身炎症性疾病 经验分享：去年9月投稿，今年7月接收，非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b21e5489896, createdName=魏骐骄, createdTime=Mon Jul 24 21:16:50 CST 2023, time=2023-07-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1247519, encodeId=5346124e5191e, content=四月份投的，现在还是reviewers invited..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Tue Sep 06 18:41:59 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098271, encodeId=d25020982e136, content=我9月初接受，大概什么时可以Proof 谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Thu Nov 03 16:27:30 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096843, encodeId=ad7120968432f, content=我的9月初接受，大家accept之后多久收到proof? 谢谢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Fri Oct 28 16:53:33 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094312, encodeId=b3fd20943120e, content=大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:51:10 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094313, encodeId=21f3209431371, content=请问大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:56:13 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236071, encodeId=f06412360e13e, content=Quality check in progress一般持续多久。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue Aug 02 00:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243361, encodeId=63001243361f7, content=审稿速度:1.0 经验分享：我想投难度大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16de5579986, createdName=ms4000001485474384, createdTime=Mon Sep 05 20:54:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199900, encodeId=d822119990079, content=偏重的研究方向：炎症 经验分享：杂志还是不错的，但是最近在pubpeer上也有几篇被质疑的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=12509f90m28暂无昵称, createdTime=Sun Mar 06 14:22:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]

2022-09-06 Aliang!!

四月份投的，现在还是reviewers invited...

51 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=1233497, encodeId=8a94123349e82, content=偏重的研究方向：炎症;慢性痛 经验分享：审稿速度很慢，Editor appointed之后日期状态换过一次，状态没变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c04b1788757, createdName=ms4708251035500551, createdTime=Tue Jul 19 21:59:37 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149644, encodeId=af1721496441f, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：自身炎症性疾病 经验分享：去年9月投稿，今年7月接收，非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b21e5489896, createdName=魏骐骄, createdTime=Mon Jul 24 21:16:50 CST 2023, time=2023-07-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1247519, encodeId=5346124e5191e, content=四月份投的，现在还是reviewers invited..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Tue Sep 06 18:41:59 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098271, encodeId=d25020982e136, content=我9月初接受，大概什么时可以Proof 谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Thu Nov 03 16:27:30 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096843, encodeId=ad7120968432f, content=我的9月初接受，大家accept之后多久收到proof? 谢谢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Fri Oct 28 16:53:33 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094312, encodeId=b3fd20943120e, content=大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:51:10 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094313, encodeId=21f3209431371, content=请问大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:56:13 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236071, encodeId=f06412360e13e, content=Quality check in progress一般持续多久。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue Aug 02 00:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243361, encodeId=63001243361f7, content=审稿速度:1.0 经验分享：我想投难度大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16de5579986, createdName=ms4000001485474384, createdTime=Mon Sep 05 20:54:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199900, encodeId=d822119990079, content=偏重的研究方向：炎症 经验分享：杂志还是不错的，但是最近在pubpeer上也有几篇被质疑的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=12509f90m28暂无昵称, createdTime=Sun Mar 06 14:22:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]

2022-11-03 124c41c1m79暂无昵称

我9月初接受，大概什么时可以Proof 谢谢

39 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=1233497, encodeId=8a94123349e82, content=偏重的研究方向：炎症;慢性痛 经验分享：审稿速度很慢，Editor appointed之后日期状态换过一次，状态没变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c04b1788757, createdName=ms4708251035500551, createdTime=Tue Jul 19 21:59:37 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149644, encodeId=af1721496441f, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：自身炎症性疾病 经验分享：去年9月投稿，今年7月接收，非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b21e5489896, createdName=魏骐骄, createdTime=Mon Jul 24 21:16:50 CST 2023, time=2023-07-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1247519, encodeId=5346124e5191e, content=四月份投的，现在还是reviewers invited..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Tue Sep 06 18:41:59 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098271, encodeId=d25020982e136, content=我9月初接受，大概什么时可以Proof 谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Thu Nov 03 16:27:30 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096843, encodeId=ad7120968432f, content=我的9月初接受，大家accept之后多久收到proof? 谢谢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Fri Oct 28 16:53:33 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094312, encodeId=b3fd20943120e, content=大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:51:10 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094313, encodeId=21f3209431371, content=请问大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:56:13 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236071, encodeId=f06412360e13e, content=Quality check in progress一般持续多久。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue Aug 02 00:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243361, encodeId=63001243361f7, content=审稿速度:1.0 经验分享：我想投难度大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16de5579986, createdName=ms4000001485474384, createdTime=Mon Sep 05 20:54:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199900, encodeId=d822119990079, content=偏重的研究方向：炎症 经验分享：杂志还是不错的，但是最近在pubpeer上也有几篇被质疑的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=12509f90m28暂无昵称, createdTime=Sun Mar 06 14:22:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]

2022-10-28 124c41c1m79暂无昵称

我的9月初接受，大家accept之后多久收到proof? 谢谢？

40 8

展开8条回复

[GetPortalCommentsPageByObjectIdResponse(id=1233497, encodeId=8a94123349e82, content=偏重的研究方向：炎症;慢性痛 经验分享：审稿速度很慢，Editor appointed之后日期状态换过一次，状态没变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c04b1788757, createdName=ms4708251035500551, createdTime=Tue Jul 19 21:59:37 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149644, encodeId=af1721496441f, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：自身炎症性疾病 经验分享：去年9月投稿，今年7月接收，非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b21e5489896, createdName=魏骐骄, createdTime=Mon Jul 24 21:16:50 CST 2023, time=2023-07-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1247519, encodeId=5346124e5191e, content=四月份投的，现在还是reviewers invited..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Tue Sep 06 18:41:59 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098271, encodeId=d25020982e136, content=我9月初接受，大概什么时可以Proof 谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Thu Nov 03 16:27:30 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096843, encodeId=ad7120968432f, content=我的9月初接受，大家accept之后多久收到proof? 谢谢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Fri Oct 28 16:53:33 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094312, encodeId=b3fd20943120e, content=大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:51:10 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094313, encodeId=21f3209431371, content=请问大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:56:13 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236071, encodeId=f06412360e13e, content=Quality check in progress一般持续多久。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue Aug 02 00:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243361, encodeId=63001243361f7, content=审稿速度:1.0 经验分享：我想投难度大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16de5579986, createdName=ms4000001485474384, createdTime=Mon Sep 05 20:54:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199900, encodeId=d822119990079, content=偏重的研究方向：炎症 经验分享：杂志还是不错的，但是最近在pubpeer上也有几篇被质疑的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=12509f90m28暂无昵称, createdTime=Sun Mar 06 14:22:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]

2022-10-17 Aliang!!

大家accept之后多久收到proof?

37 0

[GetPortalCommentsPageByObjectIdResponse(id=1233497, encodeId=8a94123349e82, content=偏重的研究方向：炎症;慢性痛 经验分享：审稿速度很慢，Editor appointed之后日期状态换过一次，状态没变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c04b1788757, createdName=ms4708251035500551, createdTime=Tue Jul 19 21:59:37 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149644, encodeId=af1721496441f, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：自身炎症性疾病 经验分享：去年9月投稿，今年7月接收，非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b21e5489896, createdName=魏骐骄, createdTime=Mon Jul 24 21:16:50 CST 2023, time=2023-07-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1247519, encodeId=5346124e5191e, content=四月份投的，现在还是reviewers invited..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Tue Sep 06 18:41:59 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098271, encodeId=d25020982e136, content=我9月初接受，大概什么时可以Proof 谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Thu Nov 03 16:27:30 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096843, encodeId=ad7120968432f, content=我的9月初接受，大家accept之后多久收到proof? 谢谢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Fri Oct 28 16:53:33 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094312, encodeId=b3fd20943120e, content=大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:51:10 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094313, encodeId=21f3209431371, content=请问大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:56:13 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236071, encodeId=f06412360e13e, content=Quality check in progress一般持续多久。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue Aug 02 00:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243361, encodeId=63001243361f7, content=审稿速度:1.0 经验分享：我想投难度大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16de5579986, createdName=ms4000001485474384, createdTime=Mon Sep 05 20:54:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199900, encodeId=d822119990079, content=偏重的研究方向：炎症 经验分享：杂志还是不错的，但是最近在pubpeer上也有几篇被质疑的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=12509f90m28暂无昵称, createdTime=Sun Mar 06 14:22:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]

2022-10-17 Aliang!!

请问大家accept之后多久收到proof?

35 0

[GetPortalCommentsPageByObjectIdResponse(id=1233497, encodeId=8a94123349e82, content=偏重的研究方向：炎症;慢性痛 经验分享：审稿速度很慢，Editor appointed之后日期状态换过一次，状态没变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c04b1788757, createdName=ms4708251035500551, createdTime=Tue Jul 19 21:59:37 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149644, encodeId=af1721496441f, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：自身炎症性疾病 经验分享：去年9月投稿，今年7月接收，非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b21e5489896, createdName=魏骐骄, createdTime=Mon Jul 24 21:16:50 CST 2023, time=2023-07-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1247519, encodeId=5346124e5191e, content=四月份投的，现在还是reviewers invited..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Tue Sep 06 18:41:59 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098271, encodeId=d25020982e136, content=我9月初接受，大概什么时可以Proof 谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Thu Nov 03 16:27:30 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096843, encodeId=ad7120968432f, content=我的9月初接受，大家accept之后多久收到proof? 谢谢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Fri Oct 28 16:53:33 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094312, encodeId=b3fd20943120e, content=大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:51:10 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094313, encodeId=21f3209431371, content=请问大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:56:13 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236071, encodeId=f06412360e13e, content=Quality check in progress一般持续多久。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue Aug 02 00:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243361, encodeId=63001243361f7, content=审稿速度:1.0 经验分享：我想投难度大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16de5579986, createdName=ms4000001485474384, createdTime=Mon Sep 05 20:54:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199900, encodeId=d822119990079, content=偏重的研究方向：炎症 经验分享：杂志还是不错的，但是最近在pubpeer上也有几篇被质疑的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=12509f90m28暂无昵称, createdTime=Sun Mar 06 14:22:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]

2022-08-02 行云流水fjsl

Quality check in progress一般持续多久。。

46 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=1233497, encodeId=8a94123349e82, content=偏重的研究方向：炎症;慢性痛 经验分享：审稿速度很慢，Editor appointed之后日期状态换过一次，状态没变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c04b1788757, createdName=ms4708251035500551, createdTime=Tue Jul 19 21:59:37 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149644, encodeId=af1721496441f, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：自身炎症性疾病 经验分享：去年9月投稿，今年7月接收，非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b21e5489896, createdName=魏骐骄, createdTime=Mon Jul 24 21:16:50 CST 2023, time=2023-07-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1247519, encodeId=5346124e5191e, content=四月份投的，现在还是reviewers invited..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Tue Sep 06 18:41:59 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098271, encodeId=d25020982e136, content=我9月初接受，大概什么时可以Proof 谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Thu Nov 03 16:27:30 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096843, encodeId=ad7120968432f, content=我的9月初接受，大家accept之后多久收到proof? 谢谢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Fri Oct 28 16:53:33 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094312, encodeId=b3fd20943120e, content=大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:51:10 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094313, encodeId=21f3209431371, content=请问大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:56:13 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236071, encodeId=f06412360e13e, content=Quality check in progress一般持续多久。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue Aug 02 00:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243361, encodeId=63001243361f7, content=审稿速度:1.0 经验分享：我想投难度大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16de5579986, createdName=ms4000001485474384, createdTime=Mon Sep 05 20:54:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199900, encodeId=d822119990079, content=偏重的研究方向：炎症 经验分享：杂志还是不错的，但是最近在pubpeer上也有几篇被质疑的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=12509f90m28暂无昵称, createdTime=Sun Mar 06 14:22:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]

2022-09-05 ms4000001485474384

审稿速度:1.0
经验分享：我想投难度大吗

46 0

[GetPortalCommentsPageByObjectIdResponse(id=1233497, encodeId=8a94123349e82, content=偏重的研究方向：炎症;慢性痛 经验分享：审稿速度很慢，Editor appointed之后日期状态换过一次，状态没变, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=58, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/img/user_icon.png, createdBy=c04b1788757, createdName=ms4708251035500551, createdTime=Tue Jul 19 21:59:37 CST 2022, time=2022-07-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2149644, encodeId=af1721496441f, content=审稿速度:12.0 | 投稿命中率:50.0 偏重的研究方向：自身炎症性疾病 经验分享：去年9月投稿，今年7月接收，非常慢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=b21e5489896, createdName=魏骐骄, createdTime=Mon Jul 24 21:16:50 CST 2023, time=2023-07-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=1247519, encodeId=5346124e5191e, content=四月份投的，现在还是reviewers invited..., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=51, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Tue Sep 06 18:41:59 CST 2022, time=2022-09-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2098271, encodeId=d25020982e136, content=我9月初接受，大概什么时可以Proof 谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=39, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Thu Nov 03 16:27:30 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2096843, encodeId=ad7120968432f, content=我的9月初接受，大家accept之后多久收到proof? 谢谢？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=8, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/10/15/f9a62fd8587c282c9381e1625c7edc6d.jpg, createdBy=4bc12513426, createdName=124c41c1m79暂无昵称, createdTime=Fri Oct 28 16:53:33 CST 2022, time=2022-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094312, encodeId=b3fd20943120e, content=大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:51:10 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2094313, encodeId=21f3209431371, content=请问大家accept之后多久收到proof?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=39e35606733, createdName=Aliang!!, createdTime=Mon Oct 17 21:56:13 CST 2022, time=2022-10-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1236071, encodeId=f06412360e13e, content=Quality check in progress一般持续多久。。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=行云流水fjsl, createdTime=Tue Aug 02 00:29:17 CST 2022, time=2022-08-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243361, encodeId=63001243361f7, content=审稿速度:1.0 经验分享：我想投难度大吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=16de5579986, createdName=ms4000001485474384, createdTime=Mon Sep 05 20:54:47 CST 2022, time=2022-09-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1199900, encodeId=d822119990079, content=偏重的研究方向：炎症 经验分享：杂志还是不错的，但是最近在pubpeer上也有几篇被质疑的文章, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=49a82534143, createdName=12509f90m28暂无昵称, createdTime=Sun Mar 06 14:22:28 CST 2022, time=2022-03-06, status=1, ipAttribution=)]

2022-03-06 12509f90m28暂无昵称

偏重的研究方向：炎症
经验分享：杂志还是不错的，但是最近在pubpeer上也有几篇被质疑的文章

43 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务